Latest news with #PfizerInc.
National Post
9 hours ago
- Business
- National Post
BenchSci Expands Board of Directors with Appointment of Dr. Mikael Dolsten
Article content Industry Veteran and Former Pfizer Chief Scientific Officer Brings Extensive R&D and Leadership Experience to Advance BenchSci's Mission of Improving the Speed and Quality of Preclinical R&D Article content TORONTO — BenchSci, a world leader in AI solutions for preclinical research and drug discovery, today announced that Mikael Dolsten, M.D., Ph.D., has joined its board of directors. Article content Dr. Dolsten, recently retired from Pfizer Inc., brings over three decades of extensive leadership and scientific expertise. During his 16-year tenure as Chief Scientific Officer and President of Pfizer Research & Development, Dr. Dolsten oversaw the regulatory approval of more than 36 medicines and vaccines. His efforts spearheaded advancements in drug discovery, with over 150 drug candidates progressing to clinical studies, and he played a vital role in the company's global response to the COVID-19 pandemic. Article content 'This is an incredible moment for BenchSci. We are honoured that Mikael has chosen to join us and lend his immense talent to our mission,' shared Liran Belenzon, CEO of BenchSci. 'Mikael's track record of leadership in pharmaceutical R&D will be invaluable as we continue to expand the reach of our AI-powered co-pilot for scientists. By helping R&D teams integrate generative AI into their workflows, we're enabling them to discover novel drug candidates faster and drive meaningful breakthroughs. Mikael's insights will be key in ensuring our technology makes a transformative impact on drug discovery.' Article content Dr. Dolsten's leadership experience spans some of the world's largest pharmaceutical organizations, including Wyeth Research, Boehringer Ingelheim, AstraZeneca, and Pharmacia. His remarkable career has been marked by contributions to approximately 50 drug and vaccine approvals, and through his VC experience, he's been involved in corporate transactions exceeding $100 billion in value. Article content 'BenchSci is doing something truly transformative with AI—redefining how we tackle preclinical research and speeding up drug discovery in ways I couldn't have imagined a decade ago,' said Mikael Dolsten, M.D., Ph.D. 'After spending my career immersed in pharmaceutical innovation, I'm inspired by the passion and vision of this team. Their work has the potential to solve some of the toughest challenges in R&D and, most importantly, bring life-saving treatments to patients faster. I'm thrilled to be part of this journey.' Article content Beyond his executive leadership roles, Dr. Dolsten has held influential positions on several public and private boards, including Agilent Technologies, Rocket Pharmaceuticals, Orbis Medicine, and Arbor Biotechnologies. Additionally, he serves as an investment advisor to leading organizations such as Blackstone Life Sciences, Google's GV, and Bain & Company. His advisory roles extend to public health initiatives, where he has collaborated with U.S. and U.K. governments and served organizations like the Scripps Research Institute and the Foundation for the NIH. Article content Since its inception, BenchSci has pioneered the application of AI through its platform, ASCEND, which acts as a scalable AI assistant for preclinical scientists. ASCEND transforms preclinical R&D by decoding biomedical research, multi-omics data, and integrating it with proprietary customer data. This creates an unbiased map of the underlying disease biology, empowering scientists to discover novel insights and accelerate R&D. ASCEND supports core functions from target identification to experimental design, validation, and translational workflows, increasing productivity. By streamlining preclinical research and prioritizing the most promising experiments, ASCEND accelerates the path to life-saving treatments. Article content BenchSci remains steadfast in its mission to solve the number one reason drug discovery projects fail—getting the biology wrong. Article content BenchSci is a world leader in AI solutions for drug discovery on a mission to exponentially increase the speed and quality of life-saving R&D to help bring new medicines to patients faster. We apply AI to understand how disease biology works throughout the drug discovery pipeline to solve the number one reason drug discovery projects fail—getting the biology wrong. Our platform, ASCEND, acts as a scalable AI assistant for preclinical organizations, increasing the productivity of the preclinical R&D pipeline across therapeutic areas. Backed by top-tier investors, including Generation, iNovia Capital, TCV, F-Prime, Gradient Ventures (Google's AI fund), and Golden Ventures, BenchSci has raised over $200 million. Our platform accelerates science at 16 top-20 pharmaceutical companies and over 4,500 leading research centers worldwide. We're a Deloitte Technology Fast 50™ and Fast 500™ winner and a certified Great Place to Work®. For more information about BenchSci, visit Article content Article content Article content Article content
Malay Mail
16-07-2025
- Health
- Malay Mail
Japan throws out nearly RM7b in expired Covid-19 medicines after demand dries up
TOKYO, July 16 — The Japanese government discarded Covid-19 oral medicines believed to be worth around 240 billion yen (RM6.85 billion) in the fiscal year through March as they had passed their expiry dates, Kyodo News Agency reported, citing health ministry officials on Wednesday. While the exact purchase price remains unclear, the value was calculated in accordance with current prices. The amount is enough to treat some 2.5 million people. The government acquired the oral drugs at the height of the coronavirus pandemic and provided them free of charge to hospitals and clinics nationwide. But many of them were unused after Covid-19 was downgraded to the same category as seasonal influenza in May 2023, which required people to pay for Covid-19 treatment. Drugmakers had also started general distribution of Covid-19 medicine in Japan themselves. A Ministry of Health, Labour and Welfare official said offering the drugs to other countries was considered but legally difficult. Among the two million doses of Pfizer Inc.'s nirmatrelvir and 1.6 million doses of Merck & Co.'s molnupiravir procured by the government, about 1.75 million doses of nirmatrelvir and some 780,000 doses of molnupiravir were disposed of, according to the ministry. The government also secured two million doses of Shionogi & Co.'s ensitrelvir but about 1.77 million of them are unused, the ministry said. They are expected to be discarded after they reach their expiration dates starting next fiscal year. — Bernama-Kyodo
The Mainichi
16-07-2025
- Health
- The Mainichi
Japan discards state-acquired COVID-19 drugs worth 240 billion yen
TOKYO (Kyodo) -- The government discarded COVID-19 oral medicines believed to be worth around 240 billion yen ($1.6 billion) in the fiscal year through March as they had passed their expiry dates, health ministry officials said Wednesday. While the exact purchase price remains unclear, the value was calculated in accordance with current prices. The amount is enough to treat some 2.5 million people. The government acquired the oral drugs at the height of the coronavirus pandemic and provided them free of charge to hospitals and clinics nationwide. But many of them were unused after COVID-19 was downgraded to the same category as seasonal influenza in May 2023, which required people to pay for COVID-19 treatment. Drugmakers had also started general distribution of COVID-19 medicine in Japan themselves. A Ministry of Health, Labor and Welfare official said offering the drugs to other countries was considered but legally difficult. Among the 2 million doses of Pfizer Inc.'s nirmatrelvir and 1.6 million doses of Merck & Co.'s molnupiravir procured by the government, about 1.75 million doses of nirmatrelvir and some 780,000 doses of molnupiravir were disposed of, according to the ministry. The government also secured 2 million doses of Shionogi & Co.'s ensitrelvir but about 1.77 million of them are unused, the ministry said. They are expected to be discarded after they reach their expiration dates starting next fiscal year.
&w=3840&q=100)
First Post
16-07-2025
- Business
- First Post
Trump signals ‘very high' pharma tariffs by Aug 1, warns rates could reach 200%
Trump has signaled plans to impose new tariffs on pharmaceuticals and semiconductors as soon as the end of July, warning that rates on drug imports could eventually soar as high as 200 percent. read more President Donald Trump recently indicated his intention to impose tariffs on pharmaceuticals and semiconductors as early as the end of July. These import taxes are likely to align with broader 'reciprocal' rates set to take effect on August 1st. 'Probably at the end of the month, and we're going to start off with a low tariff and give the pharmaceutical companies a year or so to build, and then we're going to make it a very high tariff,' Trump said STORY CONTINUES BELOW THIS AD Trump, speaking to reporters while returning to Washington from artificial intelligence summit, stated that pharmaceutical tariffs would initially be low, giving companies about a year to bring manufacturing back to the US, before escalating to very high rates. He also mentioned a 'similar' and 'less complicated' timeline for semiconductor tariffs, though he didn't offer specifics. Earlier in the month, Trump had publicly discussed a 50 per cent tariff on copper and predicted pharmaceutical tariffs could reach 200 per cent after a year-long grace period for companies to reshore production. These moves stem from investigations under Section 232 of the Trade Expansion Act of 1962, where Trump argued that a surge of foreign imports posed a threat to national security. 'I would say India, and we have a couple of others, but I have to tell you, for the most part, I'm very happy with the letters,' Trump said. These potential tariffs could immediately affect major drugmakers like Eli Lilly & Co., Merck & Co., and Pfizer Inc., which have significant overseas production. This, in turn, risks driving up costs for American consumers. Similarly, semiconductor tariffs are expected to impact not only chip manufacturers but also popular products such as laptops and smartphones from companies like Apple Inc. and Samsung Electronic Co Ltd. STORY CONTINUES BELOW THIS AD Trump's tariff threats come amidst his recent practice of unilaterally dictating tariff rates to various trading partners via letters, while simultaneously asserting his willingness to negotiate. For example, he announced an agreement with Indonesia that reduced a previously announced 32 per cent tariff to 19 per cent, in exchange for Indonesia's commitment to purchase $15 billion in US energy, $4.5 billion in agricultural products, and 50 Boeing Co. jets. Trump predicted he could finalize 'two or three' trade deals before the August 1st implementation of his 'reciprocal tariffs,' with an agreement with India being among the most likely. He acknowledged substantive discussions with five to six countries but indicated he was often content with simply dictating a tariff rate rather than finalizing a full agreement. He also suggested a standard tariff of 'a little over 10 per cent' for smaller countries not receiving tailored rates. While some countries, like South Korea, have shown a willingness to 'open' trade after his threats, others, such as Japan, have not. Representatives from the European Union, facing a 30 per cent tariff, were expected to meet with U.S. negotiators. STORY CONTINUES BELOW THIS AD Trump also dismissed concerns that his recent threat of 'secondary' tariffs on Russian trading partners—if Moscow didn't agree to a ceasefire with Ukraine—could impact US consumers, despite expert warnings that such a move could drive up energy costs. He simply stated, 'I don't think so. I think that whole thing is going to go away.'
Yahoo
29-05-2025
- Business
- Yahoo
Abrysvo or Arexvy Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2024, 2024-2029F, 2034F
This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market. Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Abrysvo or Arexvy Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to growth during the historic period can be attributed to an aging population, the launch of vaccination programs, increased awareness of respiratory illnesses, government health initiatives, and seasonal respiratory illness outbreaks. Major companies operating in the abrysvo or arexvy market are Pfizer Inc. and GlaxoSmithKline plc (GSK). North America was the largest region in the abrysvo or arexvy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast during the market's forecast period can be attributed to the expanding elderly population, increased vaccine access and global distribution, a greater emphasis on preventative healthcare, a rising incidence of respiratory infections, and improved healthcare policies and coverage. Key trends in the forecast period include advancements in vaccine technology, personalized medicine, integration of wearable health technology, innovations in vaccine delivery, cold chain logistics, and smart growing prevalence of respiratory syncytial virus (RSV) infections is expected to drive the growth of the abrysvo or arexvy market in the future. RSV infections are caused by the respiratory syncytial virus, a common virus that primarily affects the respiratory system, leading to mild cold-like symptoms in most individuals, but potentially severe illness in infants, older adults, and those with weakened immune systems. The increasing prevalence of RSV infections is fueled by the virus's highly contagious nature, seasonal outbreaks, lack of widespread immunity, and heightened vulnerability among populations such as infants and the elderly. Abrysvo helps address this issue by providing targeted vaccines to protect high-risk groups, such as older adults and infants, from severe RSV-related illnesses. For example, in October 2024, the Centers for Disease Control and Prevention (CDC), a US-based health protection agency, reported that during the 2024-25 season, the hospitalization rate for RSV was 3.2 per 100,000 individuals. As a result, the rising prevalence of RSV infections is driving the growth of the abrysvo or arexvy increase in healthcare expenditure is also expected to support the growth of the abrysvo or arexvy market. Healthcare expenditure refers to the financial investment made by governments, private insurers, and individuals into the healthcare system to enhance and expand medical services. This rise in healthcare expenditure is driven by factors such as an aging population, advancements in medical technology, the growing prevalence of chronic diseases, a higher demand for healthcare services, and rising costs of pharmaceuticals and treatments. Increased healthcare spending provides more financial resources for advanced treatment options, including biologic therapies, which benefits the Abrysvo or Arexvy market. For instance, in May 2023, the Office for National Statistics, a UK government department, reported that healthcare spending in the UK increased by 5.6% from 2022 to 2023, compared to a growth rate of 0.9% in 2022. The total healthcare expenditure in the UK amounted to approximately $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare expenditure is contributing to the growth of the abrysvo or arexvy market.A key trend in the abrysvo or arexvy market is the expansion of age indications to extend the vaccine's use to a broader range of age groups, thereby enhancing public health protection and increasing market reach. The bivalent RSV prefusion F (RSVpreF) vaccine is designed to provide immunity against respiratory syncytial virus (RSV), targeting both the RSV-A and RSV-B subtypes. For example, in October 2024, Pfizer Inc., a US-based pharmaceutical company, received FDA approval for ABRYSVO (RSV Vaccine), a bivalent RSVpreF vaccine, to prevent lower respiratory tract disease in adults aged 18 to 59 at increased risk, thus broadening its indication to a wider adult population. It remains the only approved RSV vaccine for pregnant individuals between 32 and 36 weeks of gestation to protect infants from birth to 6 Topics Covered: 1. Executive Summary2. Abrysvo or Arexvy Market Characteristics3. Abrysvo or Arexvy Market Biologic Drug Characteristics3.1. Molecule Type3.2. Route of Administration (ROA)3.3. Mechanism of Action (MOA)3.4. Safety and Efficacy4. Abrysvo or Arexvy Market Trends and Strategies5. Abrysvo or Arexvy Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market6. Global Abrysvo or Arexvy Growth Analysis and Strategic Analysis Framework6.1. Global Abrysvo or Arexvy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)6.2. Analysis of End Use Industries6.3. Global Abrysvo or Arexvy Market Growth Rate Analysis6.4. Global Abrysvo or Arexvy Historic Market Size and Growth, 2019-2024, Value ($ Million)6.5. Global Abrysvo or Arexvy Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Million)6.6. Global Abrysvo or Arexvy Total Addressable Market (TAM)7. Global Abrysvo or Arexvy Pricing Analysis & Forecasts8. Abrysvo or Arexvy Market Segmentation8.1. Global Abrysvo or Arexvy Market, Segmentation by Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million Respiratory Syncytial Virus (RSV) Prevention Infant Protection 8.2. Global Abrysvo or Arexvy Market, Segmentation by Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million Adults (18-59 years) Older Adults (60+ years) Pregnant Individuals (32-36 weeks of gestation) 8.3. Global Abrysvo or Arexvy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million Healthcare Providers Pregnant Individuals High-Risk Adults 9. Global Abrysvo or Arexvy Epidemiology of Clinical Indications9.1. Drug Side Effects9.2. Incidence and Prevalence of Clinical Indications10. Abrysvo or Arexvy Market Regional and Country Analysis10.1. Global Abrysvo or Arexvy Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million10.2. Global Abrysvo or Arexvy Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ MillionCompanies Featured Pfizer Inc. GlaxoSmithKline plc (GSK) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
